101066-87-9Relevant articles and documents
Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer
Yu, Jiang,Zhang, Lanxi,Yan, Guoyi,Zhou, Peiting,Cao, Chaoguo,Zhou, Fei,Li, Xinghai,Chen, Yuanwei
, p. 265 - 281 (2019)
Prostate cancer (PC) is the second most common malignancy in men worldwide. Among current therapies, two antiandrogens, Abiraterone Acetate and Enzalutamide (Enza) have become the standard of care for patients with metastatic castration-resistant prostate
Visible-Light photoredox decarboxylation of perfluoroarene iodine(III) Trifluoroacetates for C-H trifluoromethylation of (Hetero)arenes
Yang, Bin,Yu, Donghai,Xu, Xiu-Hua,Qing, Feng-Ling
, p. 2839 - 2843 (2018/04/14)
A scalable and operationally simple decarboxylative trifluoromethylation of (hetero)arenes with easily accessible C6F5I(OCOCF3)2 under photoredox catalysis has been developed. This method is tolerant of various (hetero)arenes and functional groups. Notably, C6F5I is recycled from the decarboxylation reaction and further used for the preparation of C6F5I(OCOCF3)2. The combination of photoredox catalysis and hypervalent iodine reagent provides a practical approach for the application of trifluoroacetic acid in trifluoromethylation reactions.
Cyclic amine compounds
-
Page/Page column 23, (2009/03/07)
The present invention relates to pharmaceutical agents which are agents for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis; the pharmaceutical agents frailty suppressants, muscle strength enhance